Celcuity gains FDA approval for closely-watched breast cancer drug
RegulatoryapprovedRevtorpykNegative
AI Analysis
Summary
Celcuity received FDA approval for breast cancer drug Revtorpyk, but shares fell nearly 20% due to announced launch delays and surprising prescribing information details.
Outcome Details
FDA approval for Revtorpyk; launch delayed; prescribing information details surprised some analysts
Importance:8/10
Sentiment:
-0.40
FDA approvalbreast cancerlaunch delaystock decline
Related Companies
Read the original article
Published by BioPharma Dive on July 15, 2026 4:18 PM